Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most statements are general hydralazine-related or speculative and are not supported by the provided FDA label excerpts for BiDil. The only clearly label-supported content is the boxed/adjunct heart failure indication in self-identified Black patients (not reflected across the listed statements). Several statements suggest use for hypertension and generic vascular relaxation, which are not supported by the provided BiDil label sections.
Category Scores
Accurate Statements
Hydralazine can cause side effects such as headache.
Label excerpt for BiDil adverse reactions (6.1) indicates headache occurs in ≥2% of patients in A-HeFT.
Hydralazine can cause side effects such as dizziness.
Label excerpt for BiDil adverse reactions (6.1) indicates dizziness occurs in ≥2% of patients in A-HeFT.
Clinicians may monitor blood pressure with hydralazine.
Label excerpt includes Hypotension risk (5.1) but does not explicitly state monitoring; this is only partially inferable from risk text and is therefore not fully supported.
Clinicians may also check blood counts with hydralazine.
No provided label excerpt states blood counts monitoring for BiDil/hydralazine.
Unsupported Statements
Hydralazine is used to lower high blood pressure (hypertension).
Provided label excerpts are for BiDil and do not state an indication for hypertension.
Hydralazine works by relaxing blood vessels.
No provided BiDil label excerpt describes this mechanism.
Hydralazine makes it easier for the heart to pump blood.
No provided BiDil label excerpt supports this phrasing as a labeled effect.
Hydralazine helps reduce the workload on the heart.
No provided BiDil label excerpt supports this statement.
Hydralazine is commonly prescribed for chronic blood pressure control.
No provided label excerpt supports this claim.
Hydralazine may be used in some settings to treat conditions related to high blood pressure that require fast vascular relaxation under clinician supervision.
No provided BiDil label excerpt supports hypertension/“fast vascular relaxation” use.
Hydralazine can be used as part of treatment regimens for certain heart-related conditions.
Overly general; the provided label excerpts specify a specific heart failure indication for BiDil but do not support this broad statement about hydralazine.
Hydralazine can cause side effects such as fast heartbeat.
Label excerpt 5.3 states hydralazine can cause tachycardia; however this is not clearly listed as an adverse reaction in the provided A-HeFT ≥2% table excerpt, and the statement is not directly supported by the provided adverse reactions list.
Clinicians may monitor blood pressure with hydralazine.
While hypotension is discussed (5.1), the provided excerpts do not explicitly recommend blood pressure monitoring.
Clinicians may also check blood counts with hydralazine.
No provided BiDil label excerpt supports blood count monitoring.
Contradictions
Important Omissions
BiDil’s FDA-labeled indication: adjunct to standard therapy for heart failure in self-identified Black patients to improve survival, prolong time to hospitalization for heart failure, and improve patient-reported functional status (including the limitation regarding NYHA class IV experience).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements imply uses (e.g., hypertension/chronic BP control) and monitoring (blood counts) not supported by the provided BiDil label excerpts. While not direct contraindication claims, these unsupported/general statements could mislead about appropriate labeled indications and required monitoring.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Predominantly general hydralazine-related claims (e.g., hypertension indication and vascular-relaxation rationale) are not supported by the provided FDA-approved BiDil label excerpts, and some monitoring claims are unsupported (e.g., blood counts).
Suggested Improvement
Restrict statements to the provided BiDil label excerpts: the specific heart failure indication in self-identified Black patients (1) and label-supported adverse reactions (6.1), plus contraindications/interactions and warnings only if explicitly quoted from the provided sections.